Feature | HRS | May 18, 2018 | Dave Fornell

Heart Rhythm 2018 Late-breaking Studies

Heart Rhythm Society (HRS) live electrophysiology (EP) procedure case at the 2018 annual meeting. #HRS2018

A live EP case presentation during the 2018 Heart Rhythm meeting.


Here is an aggregation of all the news and late-breaking studies presented at the 2018 Heart Rhythm Society (HRS) Scientific Sessions in May. 

 

Late-breaking Studies:

• Catheter Ablation vs. Antiarrhythmic Drug Therapy for Atrial Fibrillation: Results of the CABANA Multicenter International Randomized Clinical Trial

• Prevention of Arrhythmia Device Infection Trial (PADIT) — Novel Antibiotics Can Help Lower EP Device Infection Rates

• A Prospective, Blinded Evaluation of a Novel Filter Designed to Reduce Inappropriate Shocks by the Subcutaneous Implantable Defibrillator

• Three-year Outcomes After Botulinum Toxin Injections into Epicardial Fat Pads for Atrial Fibrillation Prevention in Patients Undergoing Coronary Artery Bypass Grafting

• Myocarditis Is an Underrecognized Etiology of Symptomatic Premature Ventricular Contractions - Insights from The Myocarditis and Ventricular Arrhythmia (MAVERIC) Registry

• Lower Adherence Direct Oral Anticoagulants Use Is Associated with Increased Risk of Thromboembolic Events Than Warfarin - Understanding the Real-world Performance of Systemic Anticoagulation in Atrial Fibrillation

• Atrial Fibrillation Burden and Impact on Mortality and Hospitalization — The CASTLE-AF Trial

• Device-related Thrombus After Left Atrial Appendage Closure with Watchman: Incidence, Predictors and Outcomes

• Randomized Controlled Trial of Cardiac Contractility Modulation in Heart Failure: The FIX-HF-5C Study

• Targeted Left Ventricular Lead Implantation in Non-Left Bundle Branch Block Patients: Primary Results of The Enhance CRT Pilot Study

• Intramural Needle Ablation for Refractory Ventricular Arrhythmias: 6-month Safety and Outcomes

• First In-human Data on the Globe Combined Multi-Electrode Contact Mapping and Ablation System for Treatment of Atrial Fibrillation

• A Randomized Pragmatic Trial of Strategies of Permanent Pacemaker Versus Implantable Cardiac Monitor in Older Patients with Syncope and Bifascicular Block

• Feasibility of Extravascular Pacing, Sensing and Defibrillation from a Novel Substernal lead: The Acute Extravascular Defibrillation, Pacing and Electrogram (ASD2) Study

• AV Synchronous Pacing with a Ventricular Leadless Pacemaker: Primary Results from the Marvel Study

• First Clinical Report of Atrial Fibrillation Ablation With Pulsed Electric Fields to Creat Elctroporation: An Ultra-Rapid, Tissue-Selective Modality for Cardiac Ablation

 

Other Key Heart Rhythm 2018 News: 

Atrial Fibrillation Patients Diagnosed With Carotid Atery Disease Face Increased Risk of Dementia

Five Key Takeaways From Heart Rhythm 2018

Heart Rhythm Society Recommends How to Prepare for Cybersecurity Threats to Cardiac Implantable Devices

Link Found Between Post-Traumatic Stress, Increased Risk of AFib

Marijuana Use Does Not Increase Risk of Arrhythmias, Might Reduce AFib Risk

Exposure to Air Pollution on Cold Days Can Trigger Sudden Cardiac Death in Women

Consumer Smart Watches Accurately Measure Paroxysmal Supraventricular Tachycardia

Radiofrequency Transseptal Needle Associated With 40 Percent Decrease in Silent Cerebral Embolism

FDA Clears Abbott's High-density Advisor HD Grid EP Mapping Catheter

Biosense Webster Launches Carto Vizigo Bi-Directional Guidance Sheath

Online ECG Monitoring Detects Paroxysmal AFib More Effectively Than Holter, Patch Methods

View photos from HRS 2018

Follow other HRS news

 

Link to the Heart Rhythm Society 2017 Late-Breaking Electrophysiology Trials
 

 

Other Late-breaking Cardiology Trials in 2018:

ACC 2018 Late-Breaking Trials

TCT 2018 Late-breaking Cardiovascular Clinical Trials

EuroPCR 2018 Late-breaking Trials in Interventional Cardiology

Heart Rhythm 2018 Late-breaking Studies

SCAI 2018 Late-breaking Clinical Trials

 

 

#HRS2018, #HRS18

Related Content

REBALANCE-HF early feasibility trial met objective of identifying responder group with demonstrated benefits in heart function, hemodynamics, and physical activity at 6 months
News
Late-Breaking Data Confirms Safety of Axon Therapies' Innovative Heart Failure Procedure and Identifies Patients Most Likely to Benefit from SAVM Therapy

October 10, 2023 — Axon Therapies, a private company focused on addressing a root cause of heart failure, announced 6 ...

Home October 10, 2023
Home
First-of-its-kind expandable cryoballoon catheter advances cryoablation therapy, addresses key limitations with traditional systems
News
Boston Scientific Receives FDA Approval for the POLARx Cryoablation System

August 9, 2023 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) ...

Home August 09, 2023
Home
Imricor, a global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation products, is pleased to announce that it has entered into a Memorandum of Understanding (MOU) with GE HealthCare.
News
Imricor Collaborates with GE HealthCare in Interventional Cardiac MRI

January 31, 2023 —Imricor, a global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation ...

Home January 31, 2023
Home
The Arrhythmia Care Team at Corewell Health Celebrate First Successful Procedures With New Genesis Robotic Cardiac Ablation System from Stereotaxis.
News
Corewell Health Grows Robotic Program to Treat Heart Rhythm Disorders with Adoption of Stereotaxis’ Genesis System

December 21, 2022 — Stereotaxis, a global leader in robotic technologies for the treatment of cardiac arrhythmias ...

Home December 21, 2022
Home
Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated announced submission of pivotal clinical data from the AcQForce Flutter trial
News
Acutus Medical Announces Submission of Premarket Approval Application for AcQBlate Force Sensing Ablation Catheter and System

October 24, 2022 — Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac ...

Home October 24, 2022
Home
Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced successful completion of patient enrollment in the company’s AcQForce Flutter Investigational Device Exemption (IDE) clinical trial which enrolled 110 patients at 21 sites globally
News
Acutus Medical Completes Enrollment in IDE Trial with its AcQBlate FORCE Sensing Ablation System

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
Denmark’s only robotic cardiac electrophysiology team is recognized for leading the world in treating the most heart rhythm patients using Stereotaxis’ advanced robotic technology.
News
Heart Centre Rigshospitalet Copenhagen Celebrates 5,000 Robotic Cardiac Ablation Procedures

May 4, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias ...

Home May 04, 2022
Home
The Acutus Medical AcQBlate Force sensing ablation catheter.
News
Acutus Medical Initiates First IDE Therapy Trial With AcQBlate Force Sensing Ablation System

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter ...

Home April 05, 2021
Home
Health Canada and the U.S. Food and Drug Administration (FDA) approved Thermedical’s degassed saline for use with its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter, currently being studied for the treatment of ventricular tachycardia (VT), a leading cause of sudden cardiac death worldwide.
News
FDA and Health Canada Approve Thermedical’s Degassed Saline to Help Reduce Risk of Stroke

June 16, 2020 – The Montreal Heart Institute (MHI) and Thermedical, a developer of thermal-ablation systems to treat ...

Home June 16, 2020
Home
The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Thermedical Durablate catheter to treat VT. #HRS20 #HRS2020 #heartrhythm2020
News
Saline Enhanced Radiofrequency Ablation May be an Effective Method to Treat Ventricular Tachycardia

May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SERF) ...

Home May 08, 2020
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now